| First Author | Mathewson N | Year | 2013 |
| Journal | Blood | Volume | 122 |
| Issue | 12 | Pages | 2062-73 |
| PubMed ID | 23863900 | Mgi Jnum | J:202233 |
| Mgi Id | MGI:5517723 | Doi | 10.1182/blood-2013-02-486373 |
| Citation | Mathewson N, et al. (2013) Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood 122(12):2062-73 |
| abstractText | Posttranslational protein modifications (PTMs) are necessary for cells to function properly. The role of PTMs in regulating immune responses, specifically those mediated by dendritic cells (DCs), which are critical for both innate and adaptive immunity, is not well understood. Utilizing multiple but complementary approaches, we determined the role of an important but less understood type of PTM, namely, neddylation, in regulating DC functions. Inhibition of neddylation suppressed the release of proinflammatory cytokines by DCs in response to Toll-like receptor, nucleotide oligomerization domain-like receptor, and noninfectious CD40L stimulation. These effects were more profound than those mediated by the proteasome inhibitor bortezomib or a commonly used antiinflammatory agent, dexamethasone. Targeting neddylation also suppressed the ability of DCs to stimulate murine allogeneic T cells in vitro and in vivo and human allogeneic T-cell responses in vitro. Mechanistic studies demonstrated that inhibition of neddylation reduced both canonical and noncanonical nuclear factor-kappaB (NF-kappaB) activity. Neddylation inhibition prevented the degradation of inhibitor-kappaB and thus reduced the translocation and activation of NF-kappaB, but without perturbation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Thus, blocking neddylation could be a novel strategy for mitigating immune-mediated disease processes. |
